OncoCyte Corporation (OCX)
NASDAQ: OCX
· Real-Time Price · USD
3.20
0.47 (17.22%)
At close: Jun 17, 2025, 3:59 PM
OncoCyte Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -58.2M | -60.66M | -43.14M | -36.14M | -39.94M | -27.78M | -56.77M | -59.61M | -59.58M | -72.9M | -63.81M | -68.28M | -70.47M | -64.1M | -34.52M | -27.5M | -26.12M |
Depreciation & Amortization | 1.72M | 1.56M | 1.33M | 1.41M | 1.54M | 1.68M | 2.63M | 3.57M | 4.48M | 5.22M | 5.03M | 4.85M | 4.97M | 4.21M | 3.47M | 3.36M | 2.12M |
Stock-Based Compensation | 1.58M | 1.57M | 1.63M | 1.89M | 2.52M | 2.89M | 4.89M | 7.47M | 8.87M | 10.04M | 9.13M | 7.8M | 7.56M | 6.84M | 6.12M | 6.05M | 5.42M |
Other Working Capital | 275K | 117K | -370K | -84K | -206K | 2.5M | 3.12M | 2.43M | 2.07M | -1.66M | -1.06M | -1.21M | 356K | 374K | -479K | 519K | -526K |
Other Non-Cash Items | 34.49M | 37.93M | 20.67M | 14.76M | 17.36M | 1.87M | 21.96M | 14.75M | 6.29M | 14.01M | 7.92M | 15.13M | 22.96M | 28.44M | 2.97M | -1.18M | -2.29M |
Deferred Income Tax | n/a | n/a | 65K | 1.97M | 1.99M | 1.99M | 1.92M | 24K | n/a | n/a | 97K | 235K | -1.56M | -9.12M | -9.38M | -9.39M | -6.89M |
Change in Working Capital | -2.18M | -1.16M | -510K | -557K | -987K | -3.97M | -3.05M | -3.71M | -2.02M | -1.94M | -1.35M | -2.33M | -2.83M | -2.2M | -3.69M | -1.37M | -1.2M |
Operating Cash Flow | -22.74M | -20.71M | -19.92M | -16.63M | -17.48M | -23.32M | -28.41M | -37.5M | -41.96M | -45.57M | -42.98M | -42.58M | -39.37M | -35.94M | -35.03M | -30.03M | -28.95M |
Capital Expenditures | -190K | -214K | -264K | -496K | -305K | -281K | -819K | -1.66M | -2.78M | -4.34M | -3.94M | -3.47M | -2.97M | -2.25M | -2.01M | -2.14M | -2.02M |
Cash Acquisitions | n/a | n/a | -354K | -123K | n/a | n/a | 354K | 123K | n/a | n/a | 11.11M | 11.11M | 6.82M | -607K | -12.04M | -12.04M | -11.76M |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | 367K | 367K | 367K | 367K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | -605K | -322K | -188K | -1.4M | -1.27M | -2.62M | -7.1M | -5.59M | -5.71M | -5.9M | -12.67M | -12.67M | -12.68M | -11.11M | -1K | -50K | -39K |
Investing Cash Flow | -795K | -512K | -61K | -1.27M | -956K | -2.3M | -3.35M | -2.91M | -4.15M | -4.34M | -3.94M | -3.47M | -7.26M | -13.96M | -14.05M | -14.23M | -13.82M |
Debt Repayment | -168K | -168K | -86K | n/a | -29K | -57K | -157K | -685K | -1.07M | -1.43M | -1.61M | -1.5M | -1.5M | -1.53M | -1.52M | -1.12M | 296K |
Common Stock Repurchased | -5.39M | -5.39M | -4.27M | -4.27M | 1.12M | 1.12M | n/a | n/a | n/a | n/a | n/a | -202K | -239K | -239K | -239K | -37K | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 37.25M | 8.59M | 9.63M | 9.79M | -1.6M | -1.6M | -1.57M | -1.54M | 4.39M | 4.42M | 4.43M | 7.03M | 3.64M | 1.88M | 3.17M | 617K | 10.33M |
Financial Cash Flow | 48.99M | 20.43M | 9.56M | 9.79M | 12.21M | 12.19M | 12.12M | 11.62M | 36.13M | 35.81M | 35.64M | 44.38M | 8.14M | 78.36M | 82.13M | 73.94M | 85.11M |
Net Cash Flow | 3.06M | -796K | -10.42M | -8.11M | -6.22M | -12.07M | -18.27M | -27.47M | -8.61M | -14.1M | -11.29M | -1.63M | -38.49M | 28.46M | 33.05M | 29.67M | 42.33M |
Free Cash Flow | -22.93M | -20.93M | -20.18M | -17.13M | -17.79M | -23.61M | -29.23M | -39.16M | -44.74M | -49.91M | -46.92M | -46.06M | -42.34M | -38.19M | -37.04M | -32.18M | -30.98M |